Navigation Links
Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
Date:10/28/2010

program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects. The company has additional pain compounds in preclinical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

CONTACT:  Jennifer Ruddock of Nektar Therapeutics, +1-650-631-4954, jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
(Date:7/30/2015)... July 30, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... the market close on Thursday, August 13, ... and webcast at 4:30pm Eastern.Conference Call and ... 4:30pm Eastern/1:30pm Pacific  Domestic: , ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... $5 Million Payment from Roche- , , ... (Nasdaq: MEMY ) today announced that it has ... R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive ... 212 patients in the Phase 2 trial, triggering a $5.0 ...
... MALVERN, Pa., Nov. 18 Arlington Medical Resources (AMR), ... diagnostic,imaging industries, finds that over $10 million of CSL ... quarter of 2008. Privigen is the newest,brand of intravenous ... of 2008. IVIG is a product created from the ...
Cached Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2
(Date:7/30/2015)... ... 2015 , ... Mullin/Ashley Associates, Inc. , an integrated ... the Service Industry Advertising Awards 12th annual national competition. , The awards ... University of Maryland Shore Regional Health. , A Gold Award was won by ...
(Date:7/30/2015)... ... 2015 , ... Google recently announced that it will be disclosing any incidents ... a June 8, 2015 article published by Nasdaq , the powerful tech company ... its computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may ...
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... ... 2015 , ... 24/7 Care At Home, a high-quality provider of comprehensive home ... the Centers for Medicare and Medicaid (CMS) have awarded its agency the highest star ... At Home’s agency is one of three top Orange County agencies to earn the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater ... comfort to patients as well as visiting friends and family during these critical moments, ... , The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2
... A toxic pollutant spread by oil spills, forest fires ... and may represent a second way in which smoking ... the annual meeting of the Orthopaedic Research Society in ... University of Rochester Medical Center identified one ingredient in ...
... Whitemark Homes, Inc.,(OTC Bulletin Board: WTMK), ... letter of,intent to acquire Metiscan Holdings, Inc. ... owned subsidiary Metiscan Technologies, Inc.,headquartered in Dallas, ... products and services that streamline the management ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a San Diego ... placed its LUMA Cervical Imaging System to detect,pre-cancers ... the,direction of Dr. Stephen Poliakoff., The LUMA ... detection of high-grade precancerous cervical abnormalities that have,the ...
... Vapotherm, the,global leader in High Flow Oxygen ... Robert Storey earned Maryland,s 2008 International,Business Leadership Award ... one of seven winners selected by the WTCI ... international,business. The award will be presented to Storey ...
... a result of mutations in a given cell that ... the University of Helsinki, Finland, has demonstrated that in ... development are mutations in the smooth muscle cells, previously ... of interactions between tissue types, and open up possibilities ...
... partner, DNA Research, officially launches Suracell ... expected to open soon, SOUTH ORANGE, N.J., ... leading provider of genetically directed,personalized age management programs, ... of worldwide partnerships to bring its cutting edge ...
Cached Medicine News:Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 2Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 3Health News:Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc. 2Health News:South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device 2Health News:South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device 3Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2
Inquire...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
Medicine Products: